A panel of Food and Drug Administration advisers on Friday unanimously endorsed an experimental Alzheimer's drug that's been shown to have modest success slowing the progression of the disease, clearing a hurdle for full agency approval.
Why it matters: Eisai and Biogen's Leqembi was found to delay cognitive decline by 27% over 18 months, but it has been plagued by safety concerns following three patient deaths during clinical trials.
Case in point: A new JAMA Open Network study found that cancer patients in states with palliative care laws, which can require health care providers to tell patients about their end-of-life treatment options, were more likely to die in the comfort of their home or in hospice carerather than a hospital bed.
Nursing facilities that take Medicaid or Medicare could face increased exposure to negligence lawsuits in the aftermath of a Supreme Court ruling in a major patients' rights case.
Driving the news: Justices ruled 7-2 on Thursday that nursing home residents can bring civil rights actions against providers over alleged abuses.
A brain chemical essential to decision-making and managing stress is emerging as another indicator ofwhy teen girls are bearing the worst of the youth mental health crisis.
The Biden administration on Thursday announced a 10-year experiment aimed at improving the way Medicare and Medicaid pay for primary care.
Why it matters: The effort, dubbed the Making Care Primary Model, will ease safety-net and independent primary care providers — including federally qualified health centers — into getting paid for the value of services they provide, rather than the volume.
